Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor

Journal of Controlled Release

Volumn 164, Issue 1, 2012, Pages 8-16

  Adulnirath, Asarasin ^a   Chung, Seung Woo ^a   Park, Jooho ^a   Hwang, Seung Rim ^a   Kim, Ji Young ^a   Yang, Victor C ^b,c   Kim, Sang Yoon ^d,e   Moon, Hyun Tae ^a   Byun, Youngro ^a,c  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Seoul National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

Author keywords

v 3 integrin; Angiogenesis inhibitor; cRGD; Heparin taurocholate; LMWH

Indexed keywords

ANGIOGENESIS INHIBITORS; CRGD; HEPARIN-TAUROCHOLATE; INTEGRINS; LMWH;

AMIDES; ENDOTHELIAL CELLS;

TUMORS;

AMIDE; ANGIOGENESIS INHIBITOR; CYCLIC ARGINYLGLYCYLASPARTYLTYROSINE KINASE; CYCLIC ARGINYLGLYCYLASPARTYLTYROSINE KINASE LOW MOLECULAR WEIGHT HEPARIN TAUROCHOLIC ACID CONJUGATE; LOW MOLECULAR WEIGHT HEPARIN; LOW MOLECULAR WEIGHT HEPARIN TAUROCHOLIC ACID CONJUGATE; PEPTIDE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; MICROTUBULES; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; PROTEIN BINDING; TAUROCHOLIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867765444     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.10.001     Document Type: Article

References (29)

1. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
2. J. Folkman What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82 1990 4 6
3. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
4. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat. Rev. Cancer 3 2003 401 410
5. J. Folkman Proceedings: tumor angiogenesis factor Cancer Res. 34 1974 2109 2113
6. R.S. Kerbel Tumor angiogenesis N. Engl. J. Med. 358 2008 2039 2049
7. R. Roskoski Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit. Rev. Oncol. Hematol. 62 2007 179 213
8. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676
9. A.J. Schraa, R.J. Kok, H.E. Moorlag, E.J. Bos, J.H. Proost, D.K. Meijer, L.F. de Leij, and G. Molema Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study Int. J. Cancer 102 2002 469 475
10. D. Cox, M. Brennan, and N. Moran Integrins as therapeutic targets: lessons and opportunities Nat. Rev. Drug Discov. 9 2010 804 820
11. B.P. Eliceiri, and D.A. Cheresh The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development J. Clin. Invest. 103 1999 1227 1230
12. P.C. Brooks, R.A. Clark, and D.A. Cheresh Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 1994 569 571
13. P.C. Brooks, A.M. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier, and D.A. Cheresh Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157 1164
14. L.E. Reynolds, L. Wyder, J.C. Lively, D. Taverna, S.D. Robinson, X. Huang, D. Sheppard, R.O. Hynes, and K.M. Hodivala-Dilke Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins Nat. Med. 8 2002 27 34
15. S. De, O. Razorenova, N.P. McCabe, T. O'Toole, J. Qin, and T.V. Byzova VEGF-integrin interplay controls tumor growth and vascularization Proc. Natl. Acad. Sci. U. S. A. 102 2005 7589 7594
16. M. Friedlander, P.C. Brooks, R.W. Shaffer, C.M. Kincaid, J.A. Varner, and D.A. Cheresh Definition of two angiogenic pathways by distinct alpha v integrins Science 270 1995 1500 1502
17. T.V. Byzova, C.K. Goldman, N. Pampori, K.A. Thomas, A. Bett, S.J. Shattil, and E.F. Plow A mechanism for modulation of cellular responses to VEGF: activation of the integrins Mol. Cell 6 2000 851 860
18. A.L. Dunehoo, M. Anderson, S. Majumdar, N. Kobayashi, C. Berkland, and T.J. Siahaan Cell adhesion molecules for targeted drug delivery J. Pharm. Sci. 95 2006 1856 1872
19. Z. Wang, W.K. Chui, and P.C. Ho Integrin targeted drug and gene delivery Expert Opin. Drug Deliv. 7 2010 159 171
20. D.J. Burkhart, B.T. Kalet, M.P. Coleman, G.C. Post, and T.H. Koch Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin Mol. Cancer Ther. 3 2004 1593 1604
21. Q. Cao, Z.B. Li, K. Chen, Z. Wu, L. He, N. Neamati, and X. Chen Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer Eur. J. Nucl. Med. Mol. Imaging 35 2008 1489 1498
22. K. Park, Y.S. Kim, G.Y. Lee, R.W. Park, I.S. Kim, S.Y. Kim, and Y. Byun Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth Pharm. Res. 25 2008 2786 2798
23. D.Y. Lee, S.W. Lee, S.K. Kim, M. Lee, H.W. Chang, H.T. Moon, Y. Byun, and S.Y. Kim Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells Pharm. Res. 26 2009 2667 2676
24. E. Lee, Y.S. Kim, S.M. Bae, S.K. Kim, S. Jin, S.W. Chung, M. Lee, H.T. Moon, O.C. Jeon, R.W. Park, I.S. Kim, Y. Byun, and S.Y. Kim Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor Int. J. Cancer 124 2009 2755 2765
25. K. Park, Y.S. Kim, G.Y. Lee, J.O. Nam, S.K. Lee, R.W. Park, S.Y. Kim, I.S. Kim, and Y. Byun Antiangiogenic effect of bile acid acylated heparin derivative Pharm. Res. 24 2007 176 185
26. K. Park, G.Y. Lee, Y.S. Kim, M. Yu, R.W. Park, I.S. Kim, S.Y. Kim, and Y. Byun Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity J. Control. Release 114 2006 300 306
27. I. Vlodavsky, N. Ilan, Y. Nadir, B. Brenner, B.Z. Katz, A. Naggi, G. Torri, B. Casu, and R. Sasisekharan Heparanase, heparin and the coagulation system in cancer progression Thromb. Res. 120 Suppl. 2 2007 S112 S120
28. L.R. Zacharski, and D.L. Ornstein Heparin and cancer Thromb. Haemost. 80 1998 10 23
29. S.A. Mousa, and L.J. Petersen Anti-cancer properties of low-molecular-weight heparin: preclinical evidence Thromb. Haemost. 102 2009 258 267